Genentech/Roche and $BIIB line up bispecific antibodies against cancer
The first in a potential multibillion-dollar family of cancer-fighting drugs by Genentech Inc. could offer an off-the-shelf alternative to effective, but limited, cell therapies.
The treatment is called bispecific because the arms of the Y-shaped antibody, an artificial protein, can simultaneously link to two different players in the fight against cancer. That effectively offers a one-two punch against the disease. For now, the FDA approval gives doctors another tool beyond chimeric antigen receptor T cell, or CAR-T, therapies that have been lauded for their potency. CAR-Ts, such as Yescarta from Gilead Sciences Inc.'s Kite Pharma and Novartis AG's Kymriah, use a patient's own cells, which are re-engineered and infused back into them in a process that can take weeks.
Lunsumio — homegrown at Genentech research and early development, or gRED — is the first in what the company believes could be a family of bispecific antibodies that eventually could expand into first-line options for patients, not just for patients who have failed other therapies. "Both of these antibodies are new approaches for treating cancers," Laport said."They are off-the-shelf or ready-to-treat, unlike cell therapies with genetic engineering, and are given for a fixed duration, for a finite amount of time. Patients are less likely to develop side effects."
日本 最新ニュース, 日本 見出し
Similar News:他のニュース ソースから収集した、これに似たニュース記事を読むこともできます。
Feeding San Diego announces new partnership with Instacart -SAN DIEGO (KUSI) – Feeding San Diego is one of the largest distributors of food to underprivileged families in San Diego. They are now partnering with Instacart to make sure as many families are helped as possible. KUSI’s Diane Tuazon went live at the Feeding San Diego Warehouse with details. Categories: Good Evening San Diego, Good Morning San Diego, Health,...
続きを読む »
Kala Pharmaceuticals stock rockets after FDA accepts IND application for PCED treatmentShares of Kala Pharmaceuticals Inc. shot up 45.7% in premarket trading Wednesday, after the biopharmaceutical company said the Food and Drug Administration...
続きを読む »
FDA Fast-Tracks Approval of Overdose Reversal Drug for OTC UseAn inexpensive overdose-reversal drug in nasal spray form is being fast-tracked by the FDA for consideration to be sold over-the-counter.
続きを読む »
Blood pressure tablets recalled due to potential cancer risks, FDA saysQuinaprill tablets are used to treat hypertension and are distributed across the United States to wholesalers, pharmacies and supermarkets.
続きを読む »
Blood pressure tablets recalled due to potential cancer risks, FDA saysLupin Pharmaceuticals Inc. issued the recall for four lots of Quinapril 20 mg and 40 mg tablets due to the presence of a nitrosamine that is above the recommended daily intake.
続きを読む »
Blood pressure tablets recalled due to potential cancer risks, FDA saysLupin Pharmaceuticals Inc. issued the recall for four lots of Quinapril 20 mg and 40 mg tablets due to the presence of a nitrosamine that is above the recommended daily intake.
続きを読む »